Is NLNK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

432 people get NLNK articles and Market Currents by email alert.

Get email alerts on NLNK »

HEADLINES:

NewLink Genetics to Be Added to NASDAQ Biotechnology Index

Marketwire (Thu, 8:10AM)
NewLink Genetics to Present Data on Cancer Immunotherapy Programs at the ASCO 2013 Annual Meeting

Marketwire (Thu, 8:05AM)
NewLink Genetics Corporation Reports First Quarter 2013 Financial Results

Marketwire (May 6, 2013)
NewLink Genetics: Looking To Join The Industry's Largest Movers
A John Hodge • Mon, Apr 29 • 3 Comments
NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference

PR Newswire (Apr 25, 2013)
NewLink Genetics Presents Preclinical Data on New IDO Pathway Inhibitor, NLG919, at AACR 2013 Annual Meeting

PR Newswire (Apr 8, 2013)
NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer

PR Newswire (Apr 4, 2013)
NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer

PR Newswire (Apr 2, 2013)
3 Immunotherapy Companies That Have Learned Their Lessons Well
Teresa Dawn • Mon, Mar 18 • 3 Comments
A Comprehensive Look At Immunotherapy - Part 2
Brian Nichols • Mon, Mar 4 • 24 Comments
NewLink Genetics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28
NewLink Genetics Reports Fourth Quarter and Full-Year 2012 Financial Results

Marketwire (Feb 28, 2013)
NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call

PR Newswire (Feb 25, 2013)
5 Speculative Biotech Stocks With Catalysts Pending
Brian Nichols • Mon, Feb 25 • 8 Comments
NewLink Genetics Corporation: A Promising Immunotherapy Company With An Upcoming Catalyst
EnhydrisPECorp • Mon, Feb 11 • 7 Comments
JPMorgan Healthcare Conference 2013: Ultra-Orphan Drug And Health IT Companies Lead The Way
Raymond Chung • Wed, Feb 6 • 4 Comments
NewLink Genetics Corporation Announces Exercise of Underwriters' Option and Closing of Public Offering of Common Stock

PR Newswire (Feb 4, 2013)
NewLink Genetics Corporation Announces Pricing of Public Offering of Common Stock

PR Newswire (Jan 30, 2013)
NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock

PR Newswire (Jan 29, 2013)
NewLink Genetics Appoints Mr. Brian Wiley as Vice President of Business Development

PR Newswire (Jan 3, 2013)

To learn more about Seeking Alpha Pro, click here.

NewLink Genetics: Looking To Join The Industry's Largest Movers
A John Hodge • Mon, Apr 29 • 3 Comments
NewLink Genetics Corporation: A Promising Immunotherapy Company With An Upcoming Catalyst
EnhydrisPECorp • Mon, Feb 11 • 7 Comments
Newlink Genetics' Pancreatic Cancer Vaccine Likely To Disappoint Investors In 2013
Robert Schwartz • Mon, Dec 31, 2012 • 54 Comments
IPO Preview: NewLink Genetics
IPOdesktop • Tue, Nov 8, 2011

3 Immunotherapy Companies That Have Learned Their Lessons Well
Teresa Dawn • Mon, Mar 18 • 3 Comments
A Comprehensive Look At Immunotherapy - Part 2
Brian Nichols • Mon, Mar 4 • 24 Comments
5 Speculative Biotech Stocks With Catalysts Pending
Brian Nichols • Mon, Feb 25 • 8 Comments
JPMorgan Healthcare Conference 2013: Ultra-Orphan Drug And Health IT Companies Lead The Way
Raymond Chung • Wed, Feb 6 • 4 Comments
4 Small Biotech Stocks That Should Continue With Large Returns In 2013
A John Hodge • Tue, Dec 25, 2012 • 6 Comments
7 Low-Price Biotechs With High Positive Equity
Heisenberg Principle • Tue, Dec 4, 2012 • 5 Comments
4 Biotech Stocks With Large 2012 Gains Still Present Significant Upside - Revisited
A John Hodge • Sun, Oct 7, 2012 • 3 Comments
A Gold Mine In Biotechnology: The Companies Poised To Benefit
Amy Baldwin • Tue, Sep 4, 2012 • 12 Comments
4 Biotech Stocks With Large 2012 Gains That Still Present Significant Upside
A John Hodge • Wed, Aug 29, 2012 • 1 Comment
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts During The Next 3 - 9 Months
Markus Aarnio • Mon, Aug 20, 2012 • 4 Comments
An Analysis Of Celgene's CVR For Abraxis
Chimera Research Group • Fri, Aug 3, 2012 • 17 Comments
4 Healthcare Companies With Insider Buys This Week
Markus Aarnio • Fri, Jul 27, 2012 • 2 Comments
All-Star Stocks
Markos Kaminis • Wed, Jul 11, 2012 • 8 Comments
Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 2
StockPandit • Fri, May 25, 2012 • 1 Comment
Keryx Will Tank Without The Success Of Zerenex
Vatalyst • Fri, Apr 20, 2012 • 9 Comments
2012 Preview: Cancer Immunotherapy Catalysts
Michael Becker • Thu, Dec 15, 2011 • 20 Comments
3 Cancer Immunotherapy Biotechs With Catalysts For 2012
Chemistfrog • Wed, Nov 16, 2011
5 IPOs On Tap This Week
Renaissance Capital IPO Research • Mon, Nov 7, 2011
The IPO Buzz: Stepping On The Accelerator
IPOScoop • Mon, Nov 7, 2011
Global IPO Market Bounces Back
Renaissance Capital IPO Research • Fri, Oct 28, 2011

NewLink Genetics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28

NewLink Genetics to Be Added to NASDAQ Biotechnology Index

Marketwire (Thu, 8:10AM)
NewLink Genetics to Present Data on Cancer Immunotherapy Programs at the ASCO 2013 Annual Meeting

Marketwire (Thu, 8:05AM)
NewLink Genetics Corporation Reports First Quarter 2013 Financial Results

Marketwire (May 6, 2013)
NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference

PR Newswire (Apr 25, 2013)
NewLink Genetics Presents Preclinical Data on New IDO Pathway Inhibitor, NLG919, at AACR 2013 Annual Meeting

PR Newswire (Apr 8, 2013)
NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer

PR Newswire (Apr 4, 2013)
NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer

PR Newswire (Apr 2, 2013)
NewLink Genetics Reports Fourth Quarter and Full-Year 2012 Financial Results

Marketwire (Feb 28, 2013)
NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call

PR Newswire (Feb 25, 2013)
NewLink Genetics Corporation Announces Exercise of Underwriters' Option and Closing of Public Offering of Common Stock

PR Newswire (Feb 4, 2013)
NewLink Genetics Corporation Announces Pricing of Public Offering of Common Stock

PR Newswire (Jan 30, 2013)
NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock

PR Newswire (Jan 29, 2013)
NewLink Genetics Appoints Mr. Brian Wiley as Vice President of Business Development

PR Newswire (Jan 3, 2013)
Clinical Data from NewLink Genetics' HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy

PR Newswire (Dec 13, 2012)
NewLink Genetics Receives European Orphan Designation for Algenpantucel-L Immunotherapy to Treat Pancreatic Cancer

PR Newswire (Nov 14, 2012)
Lota S. Zoth joins NewLink's Board of Directors; heads Audit Committee

PR Newswire (Nov 7, 2012)
NewLink Genetics Corporation Reports Third Quarter 2012 Financial Results

Marketwire (Oct 31, 2012)
NewLink Genetics Launches Phase 3 Clinical Trial of algenpantucel-L Immunotherapy in Patients with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

PR Newswire (Oct 10, 2012)
NewLink Genetics Launches Adaptive Design Phase 2B/3 Clinical Trial of tergenpumatucel-L Immunotherapy in Patients with Non-Small Cell Lung Cancer

PR Newswire (Oct 3, 2012)
NewLink to Present at 3rd Annual Cancer Immunotherapy Conference

PR Newswire (Oct 2, 2012)

NLNK vs. ETF Alternatives

Company Description

Currently, there's no company description for NLNK.

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 3:23 PM NewLink Genetics (NLNK +2.1%) moves up after being selected for addition to the NASDAQ Biotechnology Index, effective prior to the market open on Monday. Comment! [Healthcare, On the Move]
Monday, May 6, 11:31 AM NewLink Genetics (NLNK -3.3%) slips after its Q1 misses estimates across the board this morning. Net losses grew on a decline in grant revenue and a jump in R&D expenses, primarily due to increased manufacturing and clinical trial costs. Looking at its pipeline, the company says it anticipates completing patient accrual for its Impress trial of algenpantucel-L for surgically resected pancreatic cancer, and it recently presented preclinical results for its second IDO pathway inhibitor drug candidate, NLG919, at the American Association for Cancer Research annual meeting. Based on the data, it plans to initiate clinical trials later this year. Comment! [Healthcare, On the Move, Earnings]
Monday, May 6, 7:51 AM NewLink Genetics (NLNK): Q1 EPS of -$0.33 misses by $0.05. Revenue of $302K misses by $108K. (PR) Comment! [Earnings, Breaking News]
Thursday, February 28, 9:43 AM NewLink Genetics (NLNK): Q4 EPS of -$0.30 beats by $0.02. Revenue of $299K misses by $110K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, November 14, 2012, 1:32 PM Newlink Genetics (NLNK +4.3%) gains today after European regulators grant orphan drug status for Algenpantucel-L, the company's off-the-shelf product candidate for treatment of pancreatic cancer. The drug is currently is in Phase III testing in the U.S. Comment! [Global & FX, Healthcare, On the Move]
Monday, June 4, 2012, 12:59 PM ASCO oncology conference: NewLink Genetics (NLNK) -6.3% despite patients enjoying improved survival rates in a Phase II trial of the company's algenpantucel-L treatment for pancreatic cancer. NewLink Genetics has also disclosed positive results in early stage trials of two other drugs (I, II). Comment! [Healthcare]

Robbster
Biotech holds include $ARQL, $CUR, $GALE, $IMUC, $NBS, $PSTI, $ STEM, $NLNK. Questioning ARQL, NLNK, but holding for now...
Mar 12, 10:21 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Robbster
So, for those following, my total development biotech portfolio as of today: $ARQL, $CUR, $DNDN, $GALE, $IMUC, $NBS, $NLNK, $PSTI, $STEM.
Jan 3, 8:24 PM
Reply (1)

• !Report Abuse
View all 1 replies
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Jan 5, 3:09 PM
• !Report Abuse
Add a reply...

140 characters

Robbster
My picks for my persona "Breakthrough Biotech Fund": PSTI, IMUC, (incumbents) GALE, NLNK, STEM (new additions). Up big on incumbents...
9/10/12
Reply (5)

• !Report Abuse
View all 5 replies
Robbster: PSTI has high expectations of revenue growth due to breakthrough disease treatments so incremental offering only suppressed price short term
9/20/12
• !Report Abuse
Robbster: So, even though each PSTI share now represents a lower percentage of the company, folks believe proceeds will be used to grow company faster
9/20/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Robbster
So, for those following, my total development biotech portfolio as of today: $ARQL, $CUR, $DNDN, $GALE, $IMUC, $NBS, $NLNK, $PSTI, $STEM.
Jan 3, 8:24 PM
Reply (1)

• !Report Abuse
View all 1 replies
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Jan 5, 3:09 PM
• !Report Abuse
Add a reply...

140 characters

Robbster
My picks for my persona "Breakthrough Biotech Fund": PSTI, IMUC, (incumbents) GALE, NLNK, STEM (new additions). Up big on incumbents...
9/10/12
Reply (5)

• !Report Abuse
View all 5 replies
Robbster: PSTI has high expectations of revenue growth due to breakthrough disease treatments so incremental offering only suppressed price short term
9/20/12
• !Report Abuse
Robbster: So, even though each PSTI share now represents a lower percentage of the company, folks believe proceeds will be used to grow company faster
9/20/12
• !Report Abuse
Add a reply...

140 characters

NLNK NewLink Genetics Corporation

NLNK

NewLink Genetics Corporation